Gout Disease Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027
Gout is the condition that is characterized by formation of excess of uric acid in body tissues that results in the formation of crystals of monosodium urate. Symptoms of gout includes intense pain, swelling, and stiffness in the joints. The progression stages of gout includes asymptomatic hyperuricemia (gout), acute gout, interval or intercritical gout, chronic tophaceous gout, and pseudogout. Anti-gout drugs are available in oral and injectable dosage form. Orally administered drugs such as nonsteroidal anti-inflammatory drugs, corticosteroids, and colchicine are equally effective in the treatment of acute gout. Most of the major brands such as Zurampic, Duzallo, Zyloprim, Celebrex, and Voltaren are available in oral dosage form in the market. Thus, availability of such orally administered drugs is expected to drive growth of global gout disease treatment market over the forecast period.
The global gout disease treatment market was valued atUS$ 2,385.7million in 2018, and is expected to exhibit a CAGR of6.7%during the forecast period (2019–2027). Ask for the Sample of the Study: https://www.coherentmarketinsights.com/insight/request-sample/3082 Increasing pipeline studies to develop novel anti-gout drugs is expected to drive the global gout disease treatment market growth over the forecast period. For instance, Arthrosi Therapeutics, will initiate phase 2 clinical trial study in December 2019 to evaluate the pharmacodynamics and pharmacokinetic profile, safety, and tolerability of AR882 (drug candidate) alone or in combination with febuxostat or allopurinol, when administered to gout patients. The study is estimated to be completed by June 2020. Moreover, increasing product approvals by regulatory authority is expected to drive growth of the gout disease treatment market. For instance, in December 2018, SunGen Pharma, a privately held company, received the U.S. FDA approval for Prednisone (generic version of Deltasone), a drug with various strengths 10 mg, 20 mg, and 50 mg tablets to treat various conditions such as arthritis, gout, blood disorders, immune system disorders, and others. Penetration of generic version of anti-gout drugs is expected to provide growth opportunities to market players, in order to increase their share in gout disease treatment market. Most of the gout drugs are associated with severe side effects, which is expected to decrease demand for these drugs. Nonsteroidal anti-inflammatory drugs (NSAIDs) may cause some gastric problems such as indigestion. In few cases, these drugs can cause gastric ulcers, bleeding, and rashes in gastrointestinal (GI) tract. Moreover, side effects such as intolerability and contraindication is expected to limit the usage of these drugs in treatment of gout. For instance, in February 2019, the U.S. Food and Drug Administration (FDA) has added a new boxed warning for febuxostat, due